Novavax, Inc. (NASDAQ:NVAX) Shares Bought by US Bancorp DE

US Bancorp DE lifted its stake in shares of Novavax, Inc. (NASDAQ:NVAX) by 3,538.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,299 shares of the biopharmaceutical company’s stock after acquiring an additional 11,961 shares during the period. US Bancorp DE’s holdings in Novavax were worth $155,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. raised its holdings in Novavax by 86.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 30,791 shares of the biopharmaceutical company’s stock valued at $389,000 after acquiring an additional 14,296 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Novavax by 1,192.7% in the third quarter. Nisa Investment Advisors LLC now owns 23,449 shares of the biopharmaceutical company’s stock valued at $296,000 after purchasing an additional 21,635 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in Novavax during the third quarter worth about $214,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Novavax by 38.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 1,598 shares during the last quarter. Finally, OmniStar Financial Group Inc. purchased a new stake in Novavax in the 3rd quarter valued at about $163,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Trading Up 1.4 %

Shares of Novavax stock opened at $7.32 on Friday. Novavax, Inc. has a twelve month low of $3.53 and a twelve month high of $23.86. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -3.24 and a beta of 2.10. The company has a fifty day moving average price of $11.35 and a 200 day moving average price of $12.38.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.11. The company had revenue of $84.51 million during the quarter, compared to analysts’ expectations of $65.80 million. During the same quarter in the prior year, the company earned ($1.26) EPS. The firm’s revenue was down 54.8% compared to the same quarter last year. Analysts forecast that Novavax, Inc. will post -1.01 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on NVAX shares. B. Riley reissued a “buy” rating and issued a $26.00 target price (up from $23.00) on shares of Novavax in a research report on Thursday, October 10th. HC Wainwright reissued a “buy” rating and set a $19.00 price objective on shares of Novavax in a research note on Tuesday. Jefferies Financial Group cut their target price on Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, October 16th. Finally, JPMorgan Chase & Co. boosted their price target on Novavax from $8.00 to $9.00 and gave the company an “underweight” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $17.83.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.